

Audit Review Table					
Western Sky Community Care (Org ID: 395329, Sub ID: 14834, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2022; Date & Timestamp - 5/19/2023 12:47:41 PM					
This submission is on the stage: Apply Plan Lock					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (Total)		69.59%	R	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (Total)		55.47%	R	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (Total)		51.34%	R	R	Reported
Childhood Immunization Status (CIS)					
Childhood Immunization Status - DTaP		66.91%	R	R	Reported
Childhood Immunization Status - IPV		82.97%	R	R	Reported
Childhood Immunization Status - MMR		79.56%	R	R	Reported
Childhood Immunization Status - Hib		81.27%	R	R	Reported
Childhood Immunization Status - Hepatitis B		83.70%	R	R	Reported
Childhood Immunization Status - VZV		79.81%	R	R	Reported
Childhood Immunization Status - Pneumococcal Conjugate		66.67%	R	R	Reported
Childhood Immunization Status - Hepatitis A		79.56%	R	R	Reported
Childhood Immunization Status - Rotavirus		65.45%	R	R	Reported
Childhood Immunization Status - Influenza		35.04%	R	R	Reported
Childhood Immunization Status - Combo 3		60.10%	R	R	Reported
Childhood Immunization Status - Combo 7		53.04%	R	R	Reported
Childhood Immunization Status - Combo 10		26.76%	R	R	Reported
Immunizations for Adolescents (IMA)					
Immunizations for Adolescents - Meningococcal		80.37%	R	R	Reported
Immunizations for Adolescents - Tdap		81.96%	R	R	Reported
Immunizations for Adolescents - HPV		29.98%	R	R	Reported
Immunizations for Adolescents - Combination 1		79.72%	R	R	Reported
Immunizations for Adolescents - Combination 2		29.04%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		37.98%	R	R	Reported
Breast Cancer Screening (BCS)					
Breast Cancer Screening		38.05%	R	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		38.44%	R	R	Reported
Colorectal Cancer Screening (COL)					
Colorectal Cancer Screening (Total)		25.76%	R	R	Reported
Chlamydia Screening in Women (CHL)					
Chlamydia Screening in Women (Total)		50.50%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)					
Appropriate Testing for Pharyngitis (Total)	Y	74.71%	R	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)					
Use of Spirometry Testing in the Assessment and Diagnosis of COPD		20.83%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)					
Pharmacotherapy Management of COPD Exacerbation - Systemic Corticosteroid	Y	50.82%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation - Bronchodilator		70.49%	R	R	Reported
Asthma Medication Ratio (AMR)					
Asthma Medication Ratio (Total)	Y	58.69%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		52.07%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)					
Persistence of Beta-Blocker Treatment After a Heart Attack	Y	71.43%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)					
Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (Total)	Y	60.18%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (Total)		64.71%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Cardiac Rehabilitation - Initiation (Total)		2.08%	R	R	Reported
Cardiac Rehabilitation - Engagement1 (Total)		1.39%	R	R	Reported
Cardiac Rehabilitation - Engagement2 (Total)		2.08%	R	R	Reported
Cardiac Rehabilitation - Achievement (Total)		1.39%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes (HBD)					

Hemoglobin A1c Control for Patients With Diabetes - HbA1c Control (<8%)		40.88%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes - Poor HbA1c Control		50.36%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		54.74%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		45.50%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
Kidney Health Evaluation for Patients With Diabetes (Total)		33.07%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Statin Therapy for Patients With Diabetes - Received Statin Therapy		48.49%	R	R	Reported
Statin Therapy for Patients With Diabetes - Statin Adherence 80%		59.58%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
Diagnosed Mental Health Disorders (Total)		23.72%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
Antidepressant Medication Management - Effective Acute Phase Treatment		60.86%	R	R	Reported
Antidepressant Medication Management - Effective Continuation Phase Treatment		43.32%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase		52.05%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase		66.00%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
Follow-Up After Hospitalization For Mental Illness - 30 days (Total)		56.22%	R	R	Reported
Follow-Up After Hospitalization For Mental Illness - 7 days (Total)		40.51%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (Total)		54.61%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (Total)		32.96%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Diagnosed Substance Use Disorders - Alcohol (Total)		4.10%	R	R	Reported
Diagnosed Substance Use Disorders - Opioid (Total)		2.98%	R	R	Reported
Diagnosed Substance Use Disorders - Other (Total)		4.72%	R	R	Reported
Diagnosed Substance Use Disorders - Any (Total)		8.86%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUJ)	Y				
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (Total)		38.91%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (Total)		25.82%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
Follow-Up After Emergency Department Visit for Substance Use - 30 days (Total)		35.96%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use - 7 days (Total)		23.15%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
Pharmacotherapy for Opioid Use Disorder (Total)		17.31%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		79.04%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		51.89%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia		68.75%	NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		52.21%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y				
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)		63.82%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)		36.18%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)		35.15%	R	R	Reported
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)					

<i>Non-Recommended Cervical Cancer Screening in Adolescent Females</i>		0.48%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
<i>Appropriate Treatment for Upper Respiratory Infection (Total)</i>		78.68%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
<i>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)</i>		54.06%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
<i>Use of Imaging Studies for Low Back Pain (Total)</i>		70.16%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
<i>Use of Opioids at High Dosage</i>		3.35%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
<i>Use of Opioids From Multiple Providers - Multiple Prescribers</i>		15.02%	R	R	Reported
<i>Use of Opioids From Multiple Providers - Multiple Pharmacies</i>		1.57%	R	R	Reported
<i>Use of Opioids From Multiple Providers - Multiple Prescribers and Multiple Pharmacies</i>		1.01%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
<i>Risk of Continued Opioid Use - >=15 Days (Total)</i>		3.16%	R	R	Reported
<i>Risk of Continued Opioid Use - >=31 Days (Total)</i>		2.13%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
<i>Adults' Access to Preventive/Ambulatory Health Services (Total)</i>		65.94%	R	R	Reported
Annual Dental Visit (ADV)	Y				
<i>Annual Dental Visit (Total)</i>		56.36%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
<i>Initiation and Engagement of Substance Use Disorder Treatment - Initiation of SUD Treatment - Total (Total)</i>		48.30%	R	R	Reported
<i>Initiation and Engagement of Substance Use Disorder Treatment - Engagement of SUD Treatment - Total (Total)</i>		15.72%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
<i>Prenatal and Postpartum Care - Timeliness of Prenatal Care</i>		78.35%	R	R	Reported
<i>Prenatal and Postpartum Care - Postpartum Care</i>		67.64%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
<i>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)</i>		64.22%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
<i>Well-Child Visits in the First 30 Months of Life (First 15 Months)</i>		55.77%	R	R	Reported
<i>Well-Child Visits in the First 30 Months of Life (15 Months-30 Months)</i>		58.03%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
<i>Child and Adolescent Well-Care Visits (Total)</i>		40.09%	R	R	Reported
Frequency of Selected Procedures (FSP)			R	R	Reported
Ambulatory Care (AMB)			R	R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPU)			R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
<i>Antibiotic Utilization for Respiratory Conditions (Total)</i>		25.13%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
<i>Childhood Immunization Status - DTaP</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - IPV</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - MMR</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - HiB</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - Hepatitis B</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - VZV</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - Pneumococcal Conjugate</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - Hepatitis A</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - Rotavirus</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - Influenza</i>			NR	NR	Not Reported
<i>Childhood Immunization Status - Combo 3</i>			NR	NR	Not Reported

Childhood Immunization Status - Combo 7			NR	NR	Not Reported
Childhood Immunization Status - Combo 10			NR	NR	Not Reported
Immunizations for Adolescents (IMA-E)					
Immunizations for Adolescents - Meningococcal			NR	NR	Not Reported
Immunizations for Adolescents - Tdap			NR	NR	Not Reported
Immunizations for Adolescents - HPV			NR	NR	Not Reported
Immunizations for Adolescents - Combination 1			NR	NR	Not Reported
Immunizations for Adolescents - Combination 2			NR	NR	Not Reported
Breast Cancer Screening (BCS-E)					
Breast Cancer Screening			NR	NR	Not Reported
Colorectal Cancer Screening (COL-E)					
Colorectal Cancer Screening (Total)			NR	NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)					
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase			NR	NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase			NR	NR	Not Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)					
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)			NR	NR	Not Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)			NR	NR	Not Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)			NR	NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
Depression Screening and Follow-Up for Adolescents and Adults - Depression Screening (Total)			NR	NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults - Follow-Up on Positive Screen (Total)			NR	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Total (Total)			NR	NR	Not Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
Depression Remission or Response for Adolescents and Adults - Follow-Up PHQ-9 (Total)			NR	NR	Not Reported
Depression Remission or Response for Adolescents and Adults - Depression Remission (Total)			NR	NR	Not Reported
Depression Remission or Response for Adolescents and Adults - Depression Response (Total)			NR	NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
Unhealthy Alcohol Use Screening and Follow-Up - Unhealthy Alcohol Use Screening (Total)			NR	NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up - Alcohol Counseling or Other Follow-Up Care (Total)			NR	NR	Not Reported
Adult Immunization Status (AIS-E)					
Adult Immunization Status - Influenza (19-65)			NR	NR	Not Reported
Adult Immunization Status - Td/Tdap (19-65)			NR	NR	Not Reported
Adult Immunization Status - Zoster (50-65)			NR	NR	Not Reported
Prenatal Immunization Status (PRS-E)					
Prenatal Immunization Status - Influenza		25.81%	R	R	Reported
Prenatal Immunization Status - Tdap		54.49%	R	R	Reported
Prenatal Immunization Status - Combination		21.84%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
Prenatal Depression Screening and Follow-Up - Depression Screening			NR	NR	Not Reported
Prenatal Depression Screening and Follow-Up - Follow-Up on Positive Screen			NR	NR	Not Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
Postpartum Depression Screening and Follow-Up - Depression Screening			NR	NR	Not Reported
Postpartum Depression Screening and Follow-Up - Follow-Up on Positive Screen			NR	NR	Not Reported